3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, Non-Hodgkin
3
Hodgkin Disease
3
Sarcoma
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms by Site
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lung Neoplasms
1
Leukemia
1
Disease Progression
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Bronchiolitis Obliterans Syndrome
1
Interventions
Cyclophosphamide
85
Rituximab
80
Peripheral Blood Stem Cell Transplantation
60
fludarabine phosphate
58
Filgrastim
40
Mycophenolic Acid
37
Whole-Body Irradiation
35
Cyclosporine
35
Radiotherapy
33
Etoposide
33
Busulfan
33
Tacrolimus
31
Antilymphocyte Serum
28
Melphalan
26
Methotrexate
22
Prednisone
19
Bortezomib
19
Methylprednisolone
16
Cytarabine
16
Vincristine
15
Lenalidomide
15
Flow Cytometry
14
Cord Blood Stem Cell Transplantation
13
sargramostim
12
Doxorubicin
12
Bendamustine Hydrochloride
12
fludarabine
11
Dexamethasone
11
Carmustine
11
Carboplatin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, B-Cell, Marginal Zone
×
abexinostat
×
Clear all
NCT00724984
2014-04-07
PCYC-0403
Pharmacyclics LLC.
Phase 1/2
Completed
55 enrolled
11 charts